MARS Bioimaging is a leading research and development group that specializes in spectral molecular imaging. Their cutting-edge Medipix technology has revolutionized the industry, allowing for photon-counting CT in clinical settings. With a strong focus on innovation, MARS Bioimaging has successfully delivered the world's first commercial pre-clinical spectral CT scanner, the MARS Microlab 5X120.

This scanner utilizes the next generation of x-ray detectors, Medipix3RX, developed in collaboration with esteemed institutions such as CERN, the University of Canterbury, and the University of Otago. MARS Bioimaging works closely with their customers to provide a wide range of spectral imaging solutions for various applications, including cancer detection and the development of novel contrast agents. Their dedication to translating research into practical clinical imaging is unmatched.

MARS Bioimaging has received numerous awards for their groundbreaking work, including the HealthTech Award for Best Translational Project and the Best Innovation in Health and Science award. They continue to push the boundaries of imaging technology and are set to launch a human extremity scanner for clinical use pending regulatory approvals. Contact MARS Bioimaging to discover how their innovative solutions can enhance your research endeavors